How Biogen’s Aduhelm Bet Became A Commercial Bust

 
• By Mandy Jackson and Mary Jo Laffler
  
Aduhelm: One Year Later
Biogen's big Aduhelm bet has resulted in big financial and personnel losses • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Market Access

More from Pink Sheet